This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
The KDIGO CKD 2024 Guidelines Part 1: Evaluation and Risk Stratification
Shedding Light on the Dense Matter of C3 Glomerulopathy
NefIgArdians of The Glomerular Galaxy
Arrhythmias with Antibiotics
Should we buy what Donor-Derived Cell-Free DNA is Selling?
LUST but do not fall in Love with POCUS yet?
The 2021 KDIGO GN Guidelines
Cycling Away from Cardiac Complications
Ponticelli still sparkles in Membranous
COVID in the Kidney: An Autopsy Series
Oral or IV Iron: Follow up from a previous #nephjc chat
A few months ago, we discussed this trial from Rajiv Agarwal and his team from Indiana, which found increased serious adverse vents with IV iron, in CKD patients. The latest issue of Kidney International now has some interesting correspondence, with two critical letters, and a substantive reply from Rajiv Agarwal.
Rajiv Agarwal
Among the criticism is one from Iain Macdougall and Simon Rogers, questioning the methodology - and why these results are different from the FIND-CKD trial (free PMC link), which did test a different IV iron formulation (iron carboxymaltose in FIND-CKD, iron sucrose in REVOKE), against a lower dose of oral iron. The reply from Dr Agarwal is worth reading in full, but this table highlights the details.
Table from Kidney International Vol 88, pg 1446-7